Navigation Links
CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
Date:10/17/2008

ns to incorporate a number of features in the study design intended to manage the issues that can confound antidepressant clinical trial results."

Depression clinical trial expert Dr. Norman Rosenthal, Medical Director of Capital Clinical Associates and one of the lead investigators of the Tyrima Phase II study noted, "The CeNeRx team gets high marks for designing a first-class clinical trial. Recent efforts to test new antidepressants have encountered technical difficulties, such as a high placebo effect, which the current trial works hard to avoid. I am optimistic that the present trial should enable us to assess the potential of Tyrima as a potentially valuable new antidepressant agent."

Similar to the mechanism of conventional monoamine oxidase A inhibitors (MAOI), the triple-action mechanism of Tyrima elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that positively affect mood and anxiety, compared to the one or two neurotransmitters addressed by most current antidepressant drugs. This triple-action mechanism has the potential to provide improved antidepressant efficacy in some patients, while the selectivity and reversibility of Tyrima are expected to reduce or eliminate the risk of food-associated cardiovascular side effects of conventional MAOIs.

"A substantial subset of patients suffering from depression responds much better to treatment with MAOIs than other therapies, yet the risk of food-associated cardiovascular side effects of conventional MAOIs have greatly restricted their use, to the disadvantage of our patients," said Dr. Alexander Bodkin, a Tyrima Phase II investigator and Director of the Clinical Psychopharmacology Research Program at McLean Hospital of Harvard Medical School. "A novel agent such as Tyrima with proven MAOI activity in the CNS and a good safety and tolerability profile would be a valuable option for the many patients whose depression is refractory to treatment with cu
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
2. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
3. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
4. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
5. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
6. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
7. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
8. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Unichem Pharmaceuticals ( USA ), Inc. ... 25 mg 1000-count bottle to the consumer level. This ... to the identification of a Clopidogrel tablet found in ... risk associated with mistakenly taking a Clopidogrel tablet instead ... experiencing Clopidogrel,s side effects which include bleeding and/or bruising. ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) today announced ... director of Warburg Pincus LLC, to the Amgen Board of ... Fred Hassan and the deep, global experience he brings ... Robert A. Bradway , chairman and chief executive officer of Amgen. ... serve Amgen well." Mr. Hassan has been Partner ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... VALLEY, Calif., Oct. 11, 2011 SensoScientific Inc, ... the Healthcare Industry, announced that its WI-FI ... are now available to more than ... of Premier healthcare members.   ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... in BRICS (Brazil, Russia, India, China, ... http://www.reportlinker.com/p0652980/Peripheral-Vascular-Devices-Market-Outlook-in-BRICS-Brazil-Russia-India-China-South-Africa-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices ...
Cached Medicine Technology:SensoScientific Awarded Contract by Premier Health Care Alliance for its Breakthrough WI-FI Temperature Monitoring System 2Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 2Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 3Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 4Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 5Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 6Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 7Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 8Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 9Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 10Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 11Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 12Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 13Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 14Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 15Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 16Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 17Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 18Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 19Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 20Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 21
(Date:7/31/2015)... ... 2015 , ... When the weather turned hot and warm-season turfgrasses, such as ... called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names ... new type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure ...
(Date:7/31/2015)... ... 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening ... first provider of Exilis non-surgical fat reduction in New York. Due to its ... large International clientele. Many patients travel to New York to get their non-surgical ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Services Administration (SAMHSA) has awarded a four-year $1.6 million ... for the Study of Violence Against Children (CSVAC). The ... nation, is going to organizations helping children and adolescents ... the nation,s capacity to provide help to children of ...
... Whether she is giving a,keynote address or visiting on ... optimism and possibility. "Only in America could someone ... a warm laugh, "I,m a physically disabled woman whose,father ... three temples,and I,m running for Town Council as a ...
... Would Allow Condom Distribution in CA Correctional,Facilities, LOS ... (SCHAC) and the California HIV Alliance,will hold a press ... front,of L.A. Central Jail, 441 Bauchet Street, LA, CA ... Inmate and Community Public Health &,Safety Act" (Swanson, D, ...
... for Poverty Research has received a major research grant ... (MOWAAF) to study the economic and demographic causes, consequences, ... Ziliak, Gatton Endowed Chair of Microeconomics and director of ... the Gatton College of Business and Economics, will serve ...
... 28 "The actions of the,Connecticut Catholic Conference ... president of American Life League. "It,s bad enough ... to claim that,the Church has never officially ruled ... Catholic Conference released a statement that allows,personnel at ...
... Cross Blue Shield of Michigan is,partnering with the Michigan ... cities to help enroll eligible uninsured children in MIChild. ... community leaders and small,business owners to help get the ... be asked to send their staffs to upcoming MIChild,enrollment ...
Cached Medicine News:Health News:Center gets national funding for child trauma research 2Health News:Center gets national funding for child trauma research 3Health News:Humor and Hope Sustain NJ Woman Through Disabling Movement Disorder, Election Campaign 2Health News:Community Leaders to Host Press Event at L.A. Central Jail Urging Governor to Sign AB 1334 2Health News:Center for Poverty Research to study senior hunger in America 2Health News:Connecticut Catholic Conference Wrong to Allow 'Plan B' in Catholic Hospitals 2Health News:Blue Cross Blue Shield of Michigan Launches Effort in Five Michigan Cities with Department of Community Health to Enroll Uninsured Children in MIChild 2
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
Medicine Products: